2019

1. Adalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results from the ENEIDA Registry

   Inflammatory Bowel Diseases, Vol. 25, Núm. 11, pp. 1862-1870

2. Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial

   Therapeutic Advances in Gastroenterology, Vol. 12